Characterization of 3H-2-oxo-quazepam binding in the human brain

  title={Characterization of 3H-2-oxo-quazepam binding in the human brain},
  author={Maria Giuseppa Corda and Osvaldo Giorgi and Biancamaria Longoni and Ennio Ongini and Sergio Montaldo and Francesco Paribello and Giovanni Biggio},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  • M. Corda, O. Giorgi, G. Biggio
  • Published 31 December 1988
  • Biology, Chemistry
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
A follow-up study of the acute behavioral effects of benzodiazepine-receptor ligands in humans: comparison of quazepam and triazolam.
Across a sufficient range of doses, the performance-impairing effects of quazepam were similar to those of triazolam, and quzepam and triazlam produced comparable dose-dependent performance impairment and increased ratings of drug effect and drowsy.
Benzodiazepine-receptor ligands in humans: acute performance-impairing, subject-rated and observer-rated effects.
The behavioral pharmacologic profile of zolpidem and triazolam was indistinguishable in that at peak effect, the absolute magnitude of drug effect was comparable across the various measures, and future research could extend the findings presented here by testing higher dosages of quazepam.
Reintroduction of quazepam: an update on comparative hypnotic and adverse effects.
  • N. Moniri
  • Psychology, Biology
    International clinical psychopharmacology
  • 2019
The purpose of this review is to provide an update on distinguishing features of quazepam with regard to its pharmacology, pharmacokinetics, sleep efficacy and potential adverse effects compared to other agents used for insomnia.


Binding of a radiolabeled triazolopyridazine to a subtype of benzodiazepine receptor in the rat cerebellum.
Describing the binding of radiolabeled CL to membranes from rat cerebellum and suggesting that it binds to the Type 1 BZ receptor in a manner different from that of a BZ drug such as FLU suggest that TPZ drugs may affect the GABA receptor complex in a different or perhaps less extensive way than the BZs.
γ‐Aminobutyric Acid and Pentobarbital Enhance 2‐[3H]Oxoquazepam Binding to Type I Benzodiazepine Recognition Sites in Rat and Human Brain
The results are consistent with the hypothesis that type I benzodiazepine recognition sites are linked functionally to the GABA recognition site and the chloride ionophore.
The sedative-hypnotic properties of quazepam, a new hypnotic agent.
In conscious, unrestrained squirrel monkeys and cats, quazepam produced sedation with less ataxia and less evidence of CNS stimulant action than flurazepAM, which should be an effective hypnotic with less potential for ataxIA, paradoxical excitation, and tolerance than florinol.
gamma-Aminobutyric acid enhancement of CL 218,872 affinity and evidence of benzodiazepine receptor heterogeneity.
The results of these studies show that GABA enhances the affinity of CL 218,872 for the central benzodiazepine receptor(s) and that the inhibition of [3H]flunitrazepam binding by CL 218-872 in bovine retina, rat cerebellum, and cerebral cortex may be explained by interactions with two classes of independent binding sites.